CL 316,243 hydrate, >=98% (HPLC), powder

Application

CL 316,243 hydrate has been used:as a β-agonists to inject mice and study its effect on the expression of mammalian major facilitator superfamily domain-containing protein (Mfsd2a)as an adrenergic agonist to stimulate adrenergic response in order to study the metabolic activity of brown, beige and white adipose tissues in mice as a β3-adrenergic agonist to inject mice for in vivo lipolytic challenge

Biochem/physiol Actions

β Adrenoceptor is expressed in a number of tissues such as heart, adipose tissue, colon and other tissues. It is associated with many different biological functions. β Adrenoceptor fills in as an objective for treating type 2 diabetes, heart failure, cachexia, obesity, metabolic disorder, issues related with bladder, colon and malignant tumor growth. Depression and anxiety can also be treated via β adrenoceptor. CL 316,243 is known to have antidiabetic action via β adrenoceptor. It is a potent stimulator of lipolysis. It also activates β3- adrenoceptors on neurons in hypothalamic areas that are important in the central regulation of appetite.

CL 316,243 is a β₃ adrenoceptor agonist; anti-obesity agent.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Wyeth. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle